1INCY Stock Overview

A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. More details

1INCY fundamental analysis
Snowflake Score
Valuation	6/6
Future Growth	4/6
Past Performance	2/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 59.3% below our estimate of its fair value

Earnings are forecast to grow 21.95% per year

Trading at good value compared to peers and industry

Analysts in good agreement that stock price will rise by 21.3%

Risk Analysis

Significant insider selling over the past 3 months

Profit margins (0.5%) are lower than last year (19.8%)

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Incyte Corporation Competitors

Philogen

BIT:PHIL

€882.3m

Recordati Industria Chimica e Farmaceutica

BIT:REC

€10.7b

BioMarin Pharmaceutical

NasdaqGS:BMRN

US$11.3b

Exelixis

NasdaqGS:EXEL

US$10.0b

Price History & Performance

Summary of share price highs, lows and changes for Incyte
Historical stock prices
Current Share Price	US$54.40
52 Week High	US$74.74
52 Week Low	US$47.33
Beta	0.68
1 Month Change	11.13%
3 Month Change	-17.07%
1 Year Change	2.72%
3 Year Change	-23.48%
5 Year Change	-37.66%
Change since IPO	-35.53%

Recent updates

Shareholder Returns

	1INCY	IT Biotechs	IT Market
7D	1.3%	-7.2%	3.1%
1Y	2.7%	0.2%	13.6%

Return vs Industry: 1INCY exceeded the Italian Biotechs industry which returned 0.2% over the past year.

Return vs Market: 1INCY underperformed the Italian Market which returned 13.6% over the past year.

Price Volatility

Is 1INCY's price volatile compared to industry and market?
1INCY volatility
1INCY Average Weekly Movement	5.7%
Biotechs Industry Average Movement	8.5%
Market Average Movement	5.5%
10% most volatile stocks in IT Market	8.9%
10% least volatile stocks in IT Market	3.4%

Stable Share Price: 1INCY has not had significant price volatility in the past 3 months compared to the Italian market.

Volatility Over Time: 1INCY's weekly volatility (6%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
1991	2,617	Herve Hoppenot	www.incyte.com

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis. Its clinical stage products include INCB123667 (CDK2) for ovarian cancer; INCB161734 (KRASG12D) for cancers; INCA33890 (TGFßR2xPD-1) for solid tumors; Ruxolitinib cream for mild to moderate hidradenitis suppurativa (HS); Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma and chronic spontaneous urticaria; INCB000262 (MRGPRX2) and INCB000547 (MRGPRX4) for systemic immune and neuro-immune disorders; INCA034460 (anti-CD122) for vitiligo; and Zilurgisertib (ALK2) for fibrodysplasia ossificans progressive.

Incyte Corporation Fundamentals Summary

How do Incyte's earnings and revenue compare to its market cap?
1INCY fundamental statistics
Market cap	€10.61b
Earnings (TTM)	€19.16m
Revenue (TTM)	€3.97b

553.8x

P/E Ratio

2.7x

P/S Ratio

Is 1INCY overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1INCY income statement (TTM)
Revenue	US$4.41b
Cost of Revenue	US$2.78b
Gross Profit	US$1.64b
Other Expenses	US$1.61b
Earnings	US$21.27m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	0.11
Gross Margin	37.05%
Net Profit Margin	0.48%
Debt/Equity Ratio	0%

How did 1INCY perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/13 20:01
End of Day Share Price	2025/05/13 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Incyte Corporation is covered by 53 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jasper Hellweg	Argus Research Company
Thomas Russo	Baird
Ishan Majumdar	Baptista Research